A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
Oncology · 2025
DOI: 10.1159/000547685 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Oncology, 2025. Verfasst von Ameer Basta und 13 weiteren Autor:innen. Beteiligte Einrichtung: USF Health Morsani College of Medicine, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Immunoconjugates, Camptothecin. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
The DESTINY-B01 trial led to trastuzumab deruxtecan (T-DXd) approval for human epidermal growth factor receptor-2 (HER2+) metastatic breast cancers (mBCs), with efficacy further confirmed by DESTINY-B03, demonstrating improved progression-free and overall survival versus trastuzumab emtansine. Despite its efficacy, T-DXd had notable adverse events (AEs), including interstitial lung disease, necessitating real-world studies on safety and tolerability. Findings from such studies may help guide treatment selection and inform risk-benefit discussion in routine clinical practice.
Methods
A real-world cohort study evaluated the safety and tolerability of T-DXd in patients with HER2+ mBC. De-identified patient data, tumor characteristics, AEs, dose modifications, and discontinuation rates due to AEs were analyzed.
Results
Between January 2020 and June 2024, 85 predominantly non-Hispanic white patients with a median age of 57 years were treated. Notably, 17.6% had an ECOG performance status of 2–3, 69.4% had 1–2 prior metastatic treatments, 94% had visceral involvement, and most received primary prophylaxis with dexamethasone and palonosetron. Approximately 29.4% initiated treatment at a reduced dose; 40% required further dose reductions, primarily due to fatigue (9.4%). Permanent discontinuation due to AEs occurred in 10.6%. Common AEs included fatigue (95.3%), alopecia (14.1%), and peripheral neuropathy (14.1%). Grade ≥3 AEs were infrequent and included neutropenia (10.6%), elevated aspartate aminotransferase (2.4%), elevated alkaline phosphatase (2.4%), and interstitial lung disease (1.2%). No grade 5 events were observed.
Conclusion
T-DXd demonstrated acceptable tolerability with manageable AEs in real-world patients with HER2+ mBC, aligning with clinical trial outcomes and supporting its continued use in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USF Health Morsani College of Medicine, Tampa, Florida, USA.
- Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
- Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
- Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA, ricardo.costa@moffitt.org.
Zitieren
APA
Basta, A., Lien, K., Sun, W., Whiting, J., Armitage, M., Soyano, A. E., Armaghani, A., Loftus, L., O Apos Connor, T., Dvir, K., Han, H. S., Soliman, H., Czerniecki, B. J., & Costa, R. L. B. (2025). A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology. https://doi.org/10.1159/000547685
Vancouver
Basta A, Lien K, Sun W, Whiting J, Armitage M, Soyano AE, et al. A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology. 2025. doi:10.1159/000547685
BibTeX
@article{Basta2025,
author = {Basta, Ameer and Lien, Kyle and Sun, Weihong and Whiting, Junmin and Armitage, Melissa and Soyano, Aixa E and Armaghani, Avan and Loftus, Loretta and O Apos Connor, Tracey and Dvir, Kathrin and Han, Hyo S and Soliman, Hatem and Czerniecki, Brian J and Costa, Ricardo L B},
title = {A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer},
journal = {Oncology},
year = {2025},
doi = {10.1159/000547685}
}
EUVIMED